Douglas K Trask

University Of Iowa

$410,572

Attributed

$410,572

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $144.5K · FY2005–07

$200K$150K$100K$50K$0

'05

'06

'07

Funding mix

By agency

NIH$410,572 · 4

By mechanism

K08$393,903 · 1

M01$16,669 · 3

Top collaborators

No co-investigators on record.

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Research Personnel”

David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
Sonia M Thomas · Research Triangle Institute$700,865,642
Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
Tracy L Nolen · Research Triangle Institute$474,487,152
David R. Weir · University Of Michigan At Ann Arbor$364,053,504
Judith S. Currier · University Of California Los Angeles$284,675,012

Research focus

Research PersonnelAmitroleCatalaseAntioxidantsApoptosisAthymic MouseBiopsyButhionine SulfoximineBystander EffectCancer CellCancer TherapyCancer TypeCarcinogenesisCaspase-3Animal ModelCell Adhesion MoleculesCell DeathCell Differentiation ProcessCell LineCell MotilityCell ProliferationCellsCell TransformationAffect

Grant awards (6)

Reactive Oxygen Species Inhibition of Oral Cancer Growth$131,301

K08 · FY2007 · CA · contact PI

ESOMEPRAZOLE TO TREAT GASTRO-ESOPHAGEAL REFLUX IN HEAD AND NECK CANCER PATIENTS$1,492

M01 · FY2007 · RR · contact PI

Reactive Oxygen Species Inhibition of Oral Cancer Growth$131,301

K08 · FY2006 · CA · contact PI

ESOMEPRAZOLE TO TREAT GASTRO-ESOPHAGEAL REFLUX IN HEAD AND NECK CANCER PATIENTS$13,235

M01 · FY2006 · RR · contact PI

Reactive Oxygen Species Inhibition of Oral Cancer Growth$131,301

K08 · FY2005 · CA

ESOMEPRAZOLE TO TREAT GASTRO-ESOPHAGEAL REFLUX IN HEAD AND NECK CANCER PATIENTS$1,942

M01 · FY2005 · RR